💊

Drug Delivery

Novel delivery platforms including lipid nanoparticles, antibody-drug conjugates, and sustained-release formulations.

Companies

Pipeline Drugs

Key People

Drug Delivery Pipeline (18 drugs)

Preclinical: 8Approved: 3Phase 1/2: 2Phase 1/2a: 1Commercial: 1Pre-clinical to Commercial: 1Phase 2: 1Phase 2/3: 1

Drug	Company	Indication	Phase	Status
AVERSA Fentanyl Patch	Nutriband	Chronic Pain (with abuse-deterrent properties)	Phase 1/2	Active
AVERSA Technology Platform	Nutriband	Abuse-deterrent formulation for other transdermal opioids & drugs with abuse potential	Preclinical	Active
Transdermal Biologics/Injectable Conversion	Nutriband	Various chronic diseases requiring injectable biologics	Preclinical	Active
ABC Syringe Infusion Pump Model 4100 (Enteral)	Atlanta Biomedical	Delivery of enteral feeds / nutrition	Approved	Commercial
ABC Syringe Infusion Pump Model 4100 (IV)	Atlanta Biomedical	Intravenous medication delivery	Approved	Commercial
ABC RPC 001-5990 Rotating Pole Clamp	Atlanta Biomedical	Medical device accessory for pump mounting	Approved	Commercial
Encube-001	Encube Ethicals	Plaque Psoriasis	Phase 1/2a	Active
Encube-002	Encube Ethicals	Acne Vulgaris	Preclinical	Active
Encube-003	Encube Ethicals	Atopic Dermatitis	Preclinical	Active
Pharmaceutical-Grade Biopolymer Portfolio	HTL Biotechnology	Excipient/Component for Drug Delivery, Cell Therapy, Medical Devices	Commercial	Active
Custom Polymer Development Services	HTL Biotechnology	Partner-specific therapeutic applications	Pre-clinical to Commercial	Active
Micropoint Patch™ (Dissolving Microneedle)	Micropoint Technologies	Dermatology (skin rejuvenation)	Phase 2	Active
Hollow Microneedle Hub for In‑Vitro Diagnostics	Micropoint Technologies	Diagnostic sampling	Preclinical	Active
modEXO Platform Programs	VesiCURE Therapeutics	Oncology and inflammatory diseases (liver, pulmonary, digestive system)	Preclinical	Active
AX-0810	ProQR	Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)	Phase 1/2	Active, Dosing
AX-1416	ProQR	Undisclosed Ophthalmic Target	Preclinical	Active
AX-1501	ProQR	Undisclosed Ophthalmic Target	Preclinical	Active
QR-4210	ProQR	Usher Syndrome (USH2A exon 13 mutations)	Phase 2/3	Development Halted